JV
Therapeutic Areas
Connect Biopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Rademikibart (CBP-201) | Moderate-to-severe atopic dermatitis | Phase 3 |
| CBP-307 | Moderate-to-severe ulcerative colitis | Phase 2 |
| CBP-174 | Pruritus associated with atopic dermatitis | Phase 2 |
Leadership Team at Connect Biopharma
ZW
Zheng Wei
Co-founder, Chairman and Chief Executive Officer
SY
Stephen Yoo
Chief Medical Officer
RS
Raymond Stevens
Co-founder and Director
TY
Taiyin Yang
Co-founder and former Chief Scientific Officer
JN
James N. Topper
Board Member
SD
Samantha Du
Board Member
GW
Gang Wang
Scientific Advisor
RI
Richard Insel
Scientific Advisor
LK
Laura K. Shawver
Board Member
DL
David L. Lacey
Scientific Advisor